XOMA Royalty Stock
XOMA Royalty Corp.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Owen Hughes Jr.
- Employees
- 14
- Market cap
- $710 M
- IPO
- 06/06/1986
- Web
- www.xoma.com
XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model…
XOMA Royalty stock: price history
1D
+0.0%
1W
+0.0%
1M
-4.1%
6M
+53.8%
YTD
+51.1%
1Y
+57.7%
2Y
+43.2%
5Y
+23.6%
10Y
+265.2%
Next earnings date
Next earnings date
No date known
Volatility around earnings
~31% weaker price swings than usual
Ask the agents about XOMA Royalty
Analyst assessment of XOMA Royalty
PRICE TARGET LOW
US$39.00
CONSENSUS
US$39.00
MEDIAN
US$39.00
PRICE TARGET HIGH
US$39.00
0
STRONG BUY
5
BUY
5
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 30/04/2026
XOMA Royalty stock metrics
P/E
24.35
P/B
4.23
EV/EBITDA
14.76
RETURN ON EQUITY
4.0%
NET MARGIN
36.2%
DEBT/EQUITY
1.1
DIVIDEND YIELD
0.0%
AS OF
31/03/2026
Free float & liquidity
FREE FLOAT
95.4%
FLOAT SHARES
11,966,162
AVG. DAILY VOLUME (30D)
360,007
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about XOMA Royalty stock
What does XOMA Royalty do?
XOMA Royalty Corp. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Owen Hughes Jr., the company employs around 14 people.
The IPO was on 06/06/1986; the stock trades on NASDAQ under the ticker XOMA.
What do analysts say about XOMA Royalty stock?
10 analysts rate the stock, the consensus is Buy (as of 30/04/2026).
The average price target is US$39.00, ranging from US$39.00 to US$39.00, with a median of US$39.00.
This is an external assessment, not a statement by Market Jury.
When does XOMA Royalty report next?
Around past earnings, price swings were roughly -31% stronger than usual.
Does XOMA Royalty pay a dividend?
Yes. The last dividend was US$0.54 per share.
The dividend yield is 0.0% (as of 31/03/2026).
Which stocks are comparable to XOMA Royalty?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get XOMA Royalty stock analyzed?
Clicking "Analyze stock" lets five strategies assess XOMA Royalty against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.